Yesterday Tandem stated they have finalized their agreement with Abbott. Per a press release;
“Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced today that they have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's world-leading continuous glucose monitoring (CGM) technology with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The companies first announced their intention to work together in October 2019, and this resulting agreement covers the technical development of device integration and associated commercial support activities.”
Sounds great until you consider . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.